Vous avez cherché: antierythropoietin (Danois - Anglais)

der er rapporteret om isolerede tilfælde af neutraliserende antierythropoietin antistofmedieret erythroblastopeni i forbindelse med neorecormonbehandling.
in isolated cases, neutralising anti erythropoietin antibody-mediated pure red cell aplasia (prca) associated with neorecormon therapy has been reported.

der er rapporteret om isolerede tilfælde af neutraliserende antierythropoietin-antistofmedieret prca i forbindelse med neorecormonbehandling.
in isolated cases, neutralising anti erythropoietin antibody-mediated pure red cell aplasia (prca) associated with neorecormon therapy has been reported.

erythroblastopeni forårsaget af neutraliserende antierythropoietin antistoffer er blevet rapporteret i forbindelse med erythropoietinterapi, herunder neorecormon.
pure red cell aplasia caused by neutralising anti-erythropoietin antibodies has been reported in association with erythropoietin therapy, including neorecormon.

prca forårsaget af neutraliserende antierythropoietin-antistoffer er blevet rapporteret i forbindelse med erythropoietinterapi, herunder neorecormon.
prca caused by neutralising anti-erythropoietin antibodies has been reported in association with erythropoietin therapy, including neorecormon.

erythroblatopeni forårsaget af neutraliserende antierythropoietin-antistoffer er blevet rapporteret i forbindelse med erythropoietinterapi, herunder neorecormon.
prca caused by neutralising anti-erythropoietin antibodies has been reported in association with erythropoietin therapy, including neorecormon.

et paradoksalt fald i hæmoglobiniveau og udvikling af svær anæmi, associeret med lavt retikulocyttal, bør føre til øjeblikkelig afbrydelse af behandlingen med epoetin, og der bør udføres en antierythropoietin-antistoftest.
a paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti- erythropoietin antibody testing.

i tilfælde af at antierythropoietin antistofmedieret erythroblastopeni diagnosticeres, skal behandling med neorecormon stoppes, og patienten bør ikke skifte til et andet erythropoietinprotein (se pkt.4. 4)
in case anti-erythropoietin antibody-mediated prca is diagnosed, therapy with neorecormon must be discontinued and patients should not be switched to another erythropoietic protein (see section 4.4) .

der er indberettet isolerede tilfælde af neutraliserende antierythropoietin-antistof-medieret pure red cell aplasia (prca) i forbindelse med behandling med aranesp, fortrinsvis hos patienter med crf, der blev behandlet subkutant.
in isolated cases, neutralising anti-erythropoietin antibody mediated pure red cell aplasia (prca) associated with aranesp therapy have been reported predominantly in patients with crf treated subcutaneously.